IP Library Granted Patent US 8,466,102
Granted Patent B2
US 8,466,102 · App. 13/421,018 · Granted Jun 18, 2013

Antimicrobial cationic peptides and formulations thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,466,102
App. No.
13/421,018
Granted
Jun 18, 2013
Kind
B2
Abstract

Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.

Claims (39)

1. A method for preventing an infection caused by a prokaryotic or eukaryotic organism at a target site, comprising applying to the target site a composition comprising an antimicrobial cationic peptide at a concentration ranging from about 0.01% to about 10% (w/w), a viscosity-increasing agent, and a solvent, wherein the cationic peptide is a peptide of up to 35 amino acids comprising 11B7CN (SEQ ID NO: 23), the viscosity-increasing agent is hydroxyethyl cellulose at a concentration of about 0.5% to about 5% (w/w), and the solvent is water and glycerin, wherein the solvent comprises glycerin at a concentration up to about 20% (w/w), and wherein the composition is a gel.

2. The method of claim 1 , wherein the infection is caused by a prokaryotic organism, wherein, the prokaryotic organism is a bacterium.

3. The method of claim 1 , wherein the infection at a target site is associated with a medical device at the target site.

4. The method of claim 3 , comprising applying the composition prior to or after inserting a medical device at the target.

5. The method of claim 3 , wherein applying the composition to the target site comprises applying the composition to the medical device prior to inserting the device at the target site.

6. The method according to claim 4 , wherein the medical device comprises a catheter.

7. The method according to claim 1 , wherein the target site is a wound.

8. The method according to claim 1 , wherein the cationic peptide 11B7CN (SEQ ID NO: 23) is at a concentration ranging from about 2.0% to about 4.0% (w/w).

9. The method according to claim 1 , wherein the glycerin in the solvent is at a concentration ranging from 9% to 11% (w/w).

10. The method according to claim 1 , wherein the hydroxyethyl cellulose is at a concentration ranging from 1% to 3% (w/w).

11. The method according to claim 1 , wherein the composition further comprises benzoic acid.

12. The method according to claim 1 , wherein the composition further comprises a monocarboxylate or dicarboxylate buffering agent at a concentration in a range of about 1 mM to about 200 mM and wherein the composition has a pH ranging from about 3.5 to about 7.

13. The method according to claim 12 , wherein the buffering agent is selected from the group consisting of acetate, fumarate, lactate, malonate, succinate, and tartrate.

14. A method for preventing an infection caused by a prokaryotic or eukaryotic organism at a target site, comprising applying to the target site a composition comprising art antimicrobial cationic peptide at a concentration ranging from about 0.01% to about 10% (w/w), a viscosity-increasing agent at a concentration of about 0.5% to about 5% (w/w), a solvent, and a monocarboxylate buffering agent at a concentration ranging from about 1 mM to about 200 mM, wherein the cationic peptide is a peptide of up to 35 amino acids comprising 11B7CN (SEQ ID NO: 23), wherein the viscosity-increasing agent is hydroxyethyl cellulose, the solvent is water and glycerin, and the monocarboxylate buffering agent is lactate, wherein the solvent comprises glycerin at a concentration up to about 20% (w/w), and wherein the composition is a gel and has a pH ranging from about 3 to about 8.

15. The method according to claim 14 , wherein the composition further comprises a preservative.

16. The method according to claim 15 , wherein the preservative comprises benzoic acid, benzyl alcohol, phenoxyethanol, methylparaben, propylparaben, or a combination thereof.

17. The method according to claim 14 , wherein the composition further comprises a second viscosity-increasing agent selected from dextran, polyvinylpyrrolidone, and hydroxypropyl methylcellulose.

18. The method according to claim 17 , wherein the second viscosity-increasing agent is dextran at a concentration ranging from about 0.1% to about 5% (w/w).

19. A method for preventing an infection caused by a prokaryotic or eukaryotie organism at a target site, comprising applying to the target site a composition comprising an antimicrobial cationic peptide at a concentration ranging from about 0.01% to about 10% (w/w), a viscosity-increasing agent at a concentration of about 0.5% to about 5% (w/w), a solvent selected from one or more of water, glycerin, propylene glycol, isopropanol, ethanol, and methanol, and a monocarboxylate buffering agent at a concentration ranging from about 1 mM to about 200 mM, wherein the cationic peptide is a peptide of up to 35 amino acids comprising 11B7CN (SEQ ID NO: 23), wherein the viscosity-increasing agent is hydroxyethyl cellulose, and wherein the composition is a gel and has a pH ranging from about 3 to about 8.

20. The method according to claim 19 , wherein the concentration of the antimicrobial cationic peptide is in a range from about 1% to about 3% (w/w).

21. The method according to claim 19 , wherein the concentration of the antimicrobial cationic peptide is in a range from about 2.5% to about 3.5% (w/w).

22. The method according to claim 20 , wherein the solvent is water and glycerin, wherein the solvent comprises glycerin at a concentration up to about 20% (w/w).

23. The method according to claim 22 , wherein the concentration of glycerin in the solvent is in a range of about 9% to about 11% (w/w).

24. The method according to claim 22 , wherein the concentration of hydroxyethyl cellulose is in a range of about 1% to about 3% (w/w).

25. The method according to claim 19 , wherein the composition has a pH ranging from about 3.5 to about 7.

26. A method for preventing acne at a target site comprising applying to the target site a composition comprising an antimicrobial cationic peptide at a concentration ranging from about 0.01% to about 10% (w/w), a viscosity-increasing agent, and a solvent, wherein the cationic peptide is a peptide of up to 35 amino acids comprising 11B7CN (SEQ ID NO: 23), the viscosity-increasing agent is hydroxyethyl cellulose at a concentration of about 0.5% to about 5% (w/w) and the solvent is water and glycerin, wherein the solvent comprises glycerin at a concentration up to about 20% (w/w), and wherein the composition is a gel.

27. The method of claim 26 , wherein the acne is acne vulgaris.

28. The method of claim 26 , wherein the acne is caused by Propionibacterium acne.

29. A method for treating or preventing inflammation at a target site, comprising applying to the target site a composition comprising an antimicrobial cationic peptide at a concentration ranging from about 0.01% to about 10% (w/w), a viscosity-increasing agent, and a solvent, wherein the cationic peptide is a peptide of up to 35 amino acids comprising 11B7CN (SEQ ID NO: 23), the viscosity-increasing agent is hydroxyethyl cellulose at a concentration of about 0.5% to about 5% (w/w), and the solvent is water and glycerin, wherein the solvent comprises glycerin at a concentration up to about 20% (w/w), and wherein the composition is a gel.

30. The method according to claim 26 , wherein the concentration of the antimicrobial cationic peptide is in a range from about 1% to about 3% (w/w).

31. The method according to claim 26 , wherein the concentration of the antimicrobial cationic peptide is in a range from about 2.5% to about 3.5% (w/w).

32. The method according to claim 26 , wherein the concentration of glycerin in the solvent is in a range of about 9% to about 11% (w/w).

33. The method according to claim 26 , wherein the concentration of hydroxyethyl cellulose is in a range of about 1% to about 3% (w/w).

34. The method according to claim 26 , wherein the composition has a pH ranging from about 3.5 to about 7.

35. The method according to claim 29 , wherein the concentration of the antimicrobial cationic peptide is in a range from about 1% to about 3% (w/w).

36. The method according to claim 29 , wherein the concentration of the antimicrobial cationic peptide is in a range from about 2.5% to about 3.5% (w/w).

37. The method according to claim 29 , wherein the concentration of glycerin in the solvent is in a range of about 9% to about 11% (w/w).

38. The method according to claim 29 , wherein the concentration of hydroxyethyl cellulose is in a range of about 1% to about 3% (w/w).

39. The method according to claim 29 , wherein the composition has a pH ranging from about 3.5 to about 7.

Assignments (1)
CHANGE OF NAME Recorded Jan 14, 2013
From: BIOWEST THERAPEUTICS INC.
To: CARRUS CAPITAL CORPORATION
Reel/Frame 029626/0166 →